10:52 AM EST, 02/06/2025 (MT Newswires) -- Revance Therapeutics ( RVNC ) has been acquired by privately held Crown Laboratories, Crown said Thursday.

Crown said its tender offer to acquire all of Revance's outstanding shares at $3.65 per share expired a minute past 11:59 pm ET on Tuesday and wasn't further extended.

The company said Revance's common shares will be delisted from the Nasdaq.